Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Drug Updates

Subcategories:AnalgesicsBiologics/DMARDs

Samsung Bioepis Humira Biosimilar Wins FDA Approval

Aakash Jagadeesh Babu and Bernard Orr  |  

(Reuters)—The U.S. Food and Drug Administration approved Samsung Bioepis Co. Ltd.’s biosimilar to AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, the health agency said on Tuesday. The drug, Hadlima, was developed by South Korea’s Samsung Bioepis and comes with a boxed warning, the FDA’s harshest. The agency flagged increased risk of serious infections, including tuberculosis…

Making Sense of Drug Pricing Legislation

  |  

A number of bills have been introduced in the 116th Congress to mitigate the impact of treatment and drug costs on U.S. patients. The ACR has reviewed the bills and supports those that most closely align with its positions on access to care.

Checkpoint Inhibitors May Be Retried after Immune Adverse Event, with Close Monitoring

Marilynn Larkin  |  

NEW YORK (Reuters Health)—After an immune-related adverse event, the risk-reward ratio for an anti-PD-1 (anti-programmed death-1) or anti-PD-L1 (anti-programmed death ligand-1) rechallenge seems to be acceptable if patients are closely monitored, researchers say. “The immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 have proven efficacy in the treatment of many cancers, but patients may experience immune-related adverse…